The future of GLP-1 agonists in migraine treatment The convergence of obesity research and neurology around GLP-1 agonists represents one of the more exciting developments in both fields
More than 100 million American adults are obese, according to federal estimates
Ozempic and Trulicity had the highest reinitiation rates, and the most common switches were from Trulicity or Victoza (liraglutide, Novo Nordisk) to Ozempic and from Ozempic to Trulicity or Mounjaro
Monitoring Report: GLP-1 RA Prescribing Trends March 2024 Data
Not only did primary analysis reveal reduced death from cardiovascular causes and non-fatal myocardial infarction overall, but prespecified secondary analysis also showed that, among patients with atherosclerotic disease and heart failure, there were reduced composite heart failure hospitalizations and cardiovascular deaths among patients taking semaglutide
Last week, the duo revealed data on survodutide, which shows benefits in weight loss
